© Owkin Inc. 2017Owkin: Socrates the French and Predictive Analytics

Artificial intelligence and machine learning powered by systems biology can organize, validate, predict and compare the overabundance of information. OWKIN builds mathematical models and algorithms that can interpret omics, visual data, biostatistics and patient profiles like never before.

Improving Outcome Via Predictive Analytics and Machine Learning
OWKIN Socrates is our flagship technology platform for clinical research. Users can easily create predictive models and optimize drug development at every stage, from target discovery to clinical trials and post-market analysis. Combining algorithmic excellence with unique access to real-world data, OWKIN Socrates integrates powerful pre-trained models using proprietary privacy-preserving transfer and federated learning technologies. Discover and develop new targets, new biomarkers and new drugs faster with OWKIN Socrates!

« Data Privacy Is a Major Concern »
OWKIN is pioneering federated learning in healthcare to overcome the data sharing problem, building collective intelligence from distributed data.

Source: Owkin France SAS 

Back to section

Editor's Note

Gilles Weinrib is Co-Founder of Owkin. He has been promising (Les Echos 16/01/2018):

Aucune des données que nous traitons ne sort de l'hôpital. “A chaque partenariat, nous y installons des serveurs pour développer les algorithmes de deep learning que l'on fait voyager d'un hôpital à l'autre sans que les datas ne bougent. » Un point majeur face à ses concurrents qui s'appuient sur le cloud où toutes les données migrent sur les serveurs des géants américains.

No data we are processing migrates outside the hospital. “With each partnership we install servers to develop the algorithms for deep learning which are sent traveling from one hospitral to the other without moving the data.” A major edge against competitors who rely on the cloud where all data migrate to servers of the American giants.
Excerpt & Translation: B2Bioworld

Get out more of PR with B2Bioworld

Related Editorial Articles

B2Bioworld offers you background information

Steering Health Data For or By? The User as Stakeholder, Expert, Citizen, Consumer, and Patient
Thomas D. Szucs, Chairman of Helsana Group, one of the largest Swiss health insurance companies, on making “big data” work and crossing traditional boundaries of managing information assets

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts

Clarifying the concept of personalised medicine: Stem Cells - a discovery tool and a potential therapeutic modality
Jonathan Knowles, past Member of the Roche Executive Committee and Head of Group Research

Transition Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Patient-centered Precision Care
Michael Christman, President of Coriell Institute about turning research on human genotyping into healthcare routine

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, past Chief Technology Officer Life Sciences at Tecan on electrowetting technology, blood diagnostic devices, weaknesses of competitors like Illumina, and prospects of clinical microfluidics

Opening up Emerging Markets for Rapid Diagnostics and Point-of-Care Assays
David Dolinger shares experience and insight. Do’s and Don’ts in developing viable tests for medical, agricultural, or food diagnostics, and bringing these to low resource countries

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

America First – America Only? Roche prepares itself for user innovation
Ursula B. Redeker, CEO of Roche Germany, the worldwide third largest region for Hoffmann-La Roche’s businesses about in-house gaps, partnerships, and managing disruptive transformations in healthcare

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only. Their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.